MARKET

BCLI

BCLI

Brainstorm Cell Therapeutics I
OTCMQB
0.560
0.000
0.00%
Closed 13:47 12/12 EST
OPEN
0.590
PREV CLOSE
0.560
HIGH
0.590
LOW
0.560
VOLUME
3.66K
TURNOVER
2.11K
52 WEEK HIGH
2.500
52 WEEK LOW
0.530
MARKET CAP
6.18M
P/E (TTM)
-0.3732
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BCLI last week (1201-1205)?
Weekly Report · 5d ago
Weekly Report: what happened at BCLI last week (1124-1128)?
Weekly Report · 12/01 09:36
Weekly Report: what happened at BCLI last week (1117-1121)?
Weekly Report · 11/24 09:38
Weekly Report: what happened at BCLI last week (1110-1114)?
Weekly Report · 11/17 09:38
BrainStorm Cell Therapeutics Reports Q3 2025 Financials and Updates
TipRanks · 11/15 04:03
Brainstorm Cell Q3 EPS $(0.19) Beats $(0.37) Estimate
Benzinga · 11/14 22:53
BrainStorm Cell Therapeutics Enters Securities Purchase Agreement
TipRanks · 11/14 22:32
BrainStorm Cell Therapeutics GAAP EPS of -$0.91, revenue of $7M
Seeking Alpha · 11/14 21:44
More
About BCLI
Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease; progressive multiple sclerosis (PMS); Alzheimer’s disease (AD); and other neurodegenerative diseases. Its NurOwn, a cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived MSCs to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. It has completed a Phase III pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells. The Company's wholly owned subsidiary, Brainstorm Cell Therapeutics Ltd. holds exclusive rights to commercialize NurOwn technology.

Webull offers Brainstorm Cell Therapeutics Inc stock information, including OTCMQB: BCLI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCLI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCLI stock methods without spending real money on the virtual paper trading platform.